MetaCap

Jaguar Health (JAGX) vs NeuroSense Therapeutics (NRSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeuroSense Therapeutics is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JAGX-95.46%NRSN-66.49%
+5%-48%-100%
Oct 7, 20261 yearNov 20, 2026
JAGX-95.26%NRSN-65.03%
+5%-48%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JAGX versus NRSN key metrics
MetricJAGXNRSN
Share price$0.227$1.28
Market cap$3.03M$3.19M
1-day change-30.58%+1.59%
EPS (TTM)$-257.15$-47.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$11.51M—
Revenue growth (YoY)-1.52%—
Net income (latest FY)$-53.58M$-11.13M
Gross margin67.21%—
Operating margin-398.82%—
Net margin-465.42%—
52-week high$981.75$24.80
52-week low$0.22$1.10
Distance from 52-week high-99.98%-94.84%
Analyst consensus—strong_buy
Avg. price target upside—+7503.91%
Average volume2.40M31.57K
Shares outstanding13.35M2.49M
Employees4717
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Jaguar Health

JAGX stock →

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

JAGX vs NRSN FAQ

Which is bigger, Jaguar Health or NeuroSense Therapeutics?

NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $3.19M compared with $3.03M for Jaguar Health (JAGX).

Are Jaguar Health and NeuroSense Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons